Patient experience of imaging reports: A systematic literature review

por Rogers, Charlie, Willis, Sophie, Gillard, Steven, Chudleigh, Jane
Publicado 2023

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer

por Kim, Seung Tae, Smith, Simon A., Mortimer, Peter, Loembé, Arsene-Bienvenu, Cho, Heejin, Kim, Kyoung-Mee, Smith, Claire, Willis, Sophie, Irurzun-Arana, Itziar, Berges, Alienor, Hong, Jung Yong, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Kozarewa, Iwanka, Pierce, Andrew J., Dean, Emma, Lee, Jeeyun
Publicado 2021

Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response

por Willis, Sophie E., Winkler, Claudia, Roudier, Martine P., Baird, Tarrion, Marco-Casanova, Paola, Jones, Emma V., Rowe, Philip, Rodriguez-Canales, Jaime, Angell, Helen K., Ng, Felicia S. L., Waring, Paul M., Hodgson, Darren, Ledermann, Jonathan A., Weberpals, Johanne I., Dean, Emma, Harrington, Elizabeth A., Barrett, J. Carl, Pierce, Andrew J., Leo, Elisabetta, Jones, Gemma N.
Publicado 2021

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

por Fok, Jacqueline H. L., Ramos-Montoya, Antonio, Vazquez-Chantada, Mercedes, Wijnhoven, Paul W. G., Follia, Valeria, James, Neil, Farrington, Paul M., Karmokar, Ankur, Willis, Sophie E., Cairns, Jonathan, Nikkilä, Jenni, Beattie, David, Lamont, Gillian M., Finlay, M. Raymond V., Wilson, Joanne, Smith, Aaron, O’Connor, Lenka Oplustil, Ling, Stephanie, Fawell, Stephen E., O’Connor, Mark J., Hollingsworth, Simon J., Dean, Emma, Goldberg, Frederick W., Davies, Barry R., Cadogan, Elaine B.
Publicado 2019